Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 4/20 | 0.50 |
| ▸ | LDLR | P01130 | 1/20 | 0.50 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.50 |
| ▸ | HPGDS | O60760 | 1/20 | 0.50 |
| ▸ | ATP1A1 | P05023 | 7/20 | 0.49 |
| ▸ | ATP1B1 | P05026 | 7/20 | 0.49 |
| ▸ | ATP1A3 | P13637 | 7/20 | 0.49 |
| ▸ | ATP1B2 | P14415 | 7/20 | 0.49 |
| ▸ | ATP1A2 | P50993 | 7/20 | 0.49 |
| ▸ | ATP1B3 | P54709 | 7/20 | 0.49 |
| ▸ | FXYD2 | P54710 | 7/20 | 0.49 |
| ▸ | ATP1A4 | Q13733 | 7/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11482311 | 0.82 | BACE1 (0.43) | CYP1A2CYP3A4CYP2D6GAALDLR | |
| SCHEMBL2107151 | 0.81 | USP2 (0.64) | CYP1A2CYP3A4CYP2D6GAAATP1A1 | |
| SCHEMBL12721184 | 0.78 | CYP1A2 (0.63) | CYP1A2CYP3A4CYP2D6GAALDLR | |
| SCHEMBL822807 | 0.78 | HPGDS (0.77) | CYP1A2CYP3A4CYP2D6GAALDLR | |
| SCHEMBL532551 | 0.76 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6GAALDLR | |
| SCHEMBL3958498 | 0.76 | CYP1A2 (0.61) | CYP1A2CYP3A4CYP2D6GAALDLR | |
| SCHEMBL27217078 | 0.76 | CYP1A2 (0.61) | CYP1A2CYP3A4CYP2D6GAALDLR | |
| SCHEMBL11482313 | 0.76 | KDM4E (0.45) | CYP1A2LMNAALDH1A1TDP1TP53 | |
| SCHEMBL14680499 | 0.76 | ALDH1A1 (0.45) | CYP1A2CYP3A4CYP2D6GAAHPGDS | |
| SCHEMBL8656696 | 0.74 | CYP1A2 (0.42) | CYP1A2CYP3A4CYP2D6GAALDLR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10196604-B2 | Mitochondrial inhibitors for use in culturing pluripotent stem cells | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-02-05 | — | — | US | disclosed |
| US-9750723-B2 | Prevention and treatment of non-alcoholic fatty liver disease | OHIO UNIVERSITY (US) | 2017-09-05 | — | — | US | disclosed |
| US-9750723-B2 | Prevention and treatment of non-alcoholic fatty liver disease | OHIO UNIVERSITY (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170130198-A1 | MITOCHONDRIAL INHIBITORS FOR USE IN CULTURING PLURIPOTENT STEM CELLS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2017-05-11 | — | — | US | disclosed |
| US-20170130198-A1 | MITOCHONDRIAL INHIBITORS FOR USE IN CULTURING PLURIPOTENT STEM CELLS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2017-05-11 | — | — | US | disclosed |
| US-20170020858-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES INC (US) | 2017-01-26 | — | — | US | disclosed |
| US-20160256439-A1 | PREVENTION AND TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE | OHIO UNIVERSITY (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160256439-A1 | PREVENTION AND TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE | OHIO UNIVERSITY (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160220536-A1 | USE OF PHENYLMETHIMAZOLES, METHIMAZOLE DERIVATIVES, AND TAUTOMERIC CYCLIC THIONES FOR THE TREATMENT OF AUTOIMMUNE/INFLAMMATORY DISEASES ASSOCIATED WITH TOLL-LIKE RECEPTOR OVEREXPRESSION | UNIV OHIO (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160220536-A1 | USE OF PHENYLMETHIMAZOLES, METHIMAZOLE DERIVATIVES, AND TAUTOMERIC CYCLIC THIONES FOR THE TREATMENT OF AUTOIMMUNE/INFLAMMATORY DISEASES ASSOCIATED WITH TOLL-LIKE RECEPTOR OVEREXPRESSION | UNIV OHIO (US) | 2016-08-04 | — | — | US | disclosed |
| US-5030644-A | Thrombolytic, fibrinolytic therapy | MERCK & CO., INC. (US) | 1991-07-09 | — | — | US | disclosed |
| EP-0411705-A1 | Imidazole compounds and their use as transglutaminase inhibitors | MERCK & CO. INC. (US) | 1991-02-06 | — | — | EP | disclosed |
| EP-0137223-B1 | PHOTOGRAPHIC IMAGE-RECEIVING ELEMENT FOR SILVER SALT DIFFUSION TRANSFER PROCESS | FUJI PHOTO FILM CO., LTD. (JP) | 1988-05-11 | — | — | EP | disclosed |
| EP-0135786-B1 | PHOTOGRAPHIC IMAGE RECEIVING ELEMENTS FOR SILVER SALT DIFFUSION TRANSFER PROCESSES | FUJI PHOTO FILM CO., LTD. (JP) | 1988-03-09 | — | — | EP | disclosed |
| US-4626495-A | HYDROPHILIC COPOLYMER LAYER CONTAINING GUM ARABIC OR ARABIC ACID COATED BETWEEN ALKALI IMPERMEABLE AND IMAGE RECEIVING LAYERS | FUJI PHOTO FILM CO., LTD. (JP) | 1986-12-02 | — | — | US | disclosed |
| US-4585725-A | STORAGE STABILITY | FUJI PHOTO FILM CO., LTD. (JP) | 1986-04-29 | — | — | US | disclosed |
| US-4569900-A | SULFONATE OR SULFATE SURFACTANTS, POLYSACCUARIDES; SUPERIOR STRIPPING, NO MARKS OR SHEAR | FUJI PHOTO FILM CO., LTD. (JP) | 1986-02-11 | — | — | US | disclosed |
| US-4568634-A | HIGH CONTRAST IMAGE | FUJI PHOTO FILM CO., LTD. (JP) | 1986-02-04 | — | — | US | disclosed |
| EP-0137223-A2 | Photographic image-receiving element for silver salt diffusion transfer process | FUJI PHOTO FILM CO., LTD. (JP) | 1985-04-17 | — | — | EP | disclosed |
| EP-0135786-A2 | Photographic image receiving elements for silver salt diffusion transfer processes | FUJI PHOTO FILM CO., LTD. (JP) | 1985-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196604-B2 | Mitochondrial inhibitors for use in culturing pluripotent stem cells | TFAM, TUFM, ALDH2 | CYP1A2 1260/4885CYP3A4 1130/4885CYP2D6 2422/4885 |
| US-20170020858-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | TRPV3, TRPV1, TRPV4 | CYP1A2 3450/4885CYP3A4 3177/4885CYP2D6 3441/4885 |
| US-20160256439-A1 | PREVENTION AND TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE | FABP1, CPT1A, LIPC | CYP1A2 95/4885CYP3A4 77/4885CYP2D6 1018/4885 |
| US-20160220536-A1 | USE OF PHENYLMETHIMAZOLES, METHIMAZOLE DERIVATIVES, AND TAUTOMERIC CYCLIC THIONES FOR THE TREATMENT OF AUTOIMMUNE/INFLAMMATORY DISEASES ASSOCIATED WITH TOLL-LIKE RECEPTOR OVEREXPRESSION | IRF3, TLR3, TLR4 | CYP1A2 3921/4885CYP3A4 1685/4885CYP2D6 4244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.